The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions

Koji Sugimoto, Lawrence V. Hofmann, Mahmood K. Razavi, Stephen T. Kee, Daniel Y. Sze, Michael D. Dake, Charles P. Semba

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to compare the efficacy, complications, and costs associated with low-dose (≤2 mg/h) alteplase (tissue plasminogen activator [t-PA]) versus urokinase for the catheter-directed treatment of acute peripheral arterial occlusive disease (PAO) and deep vein thrombosis (DVT). Materials and methods: A retrospective review was performed during sequential time periods on two groups with involved extremities treated with either t-PA with subtherapeutic heparin (TPA group) or urokinase with full heparin (UK group) at a single center. Treatment group characteristics, success rates, complications, dosages, infusion time, and costs were compared. Results: Eighty-nine patients with 93 involved limbs underwent treatment (54 with DVT, 39 with PAO). The treatment groups were statistically identical (TPA: 45 limbs; 24 with DVT, 53.3%; 21 with PAO, 46.7%; UK: 48 limbs; 30 with DVT, 62.5%; 18 with PAO, 37.5%). The overall average hourly infused dose, total dose, infusion time, success rates, and cost of thrombolytic agent were as follows (± standard deviation): TPA, 0.86 ± 0.50 mg/h, 21.2 ± 15.1 mg, 24.6 ± 11.2 hours, 89.4%, $466 ± $331; and UK, 13.5 ± 5.6 (10 4 ) U/h, 4.485 ± 2.394 million U, 33.3 ± 13.3 hours, 85.7%, $6871 ± $3667, respectively. Major and minor complication rates were: TPA, 2.2% and 8.9%; and UK, 2.1% and 10.4%, respectively. No statistical differences in success rates or complications were observed; however, t-PA was significantly (P < .05) less expensive and faster than urokinase. Conclusion: Low-dose t-PA combined with subtherapeutic heparin is equally efficacious and safe compared with urokinase. Infusions with t-PA were significantly shorter and less expensive than those with urokinase.

Original languageEnglish (US)
Pages (from-to)512-517
Number of pages6
JournalJournal of vascular surgery
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Urokinase-Type Plasminogen Activator
Tissue Plasminogen Activator
Arterial Occlusive Diseases
Catheters
Peripheral Arterial Disease
Safety
Venous Thrombosis
Extremities
Heparin
Costs and Cost Analysis
Fibrinolytic Agents
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. / Sugimoto, Koji; Hofmann, Lawrence V.; Razavi, Mahmood K.; Kee, Stephen T.; Sze, Daniel Y.; Dake, Michael D.; Semba, Charles P.

In: Journal of vascular surgery, Vol. 37, No. 3, 01.03.2003, p. 512-517.

Research output: Contribution to journalArticle

Sugimoto, Koji ; Hofmann, Lawrence V. ; Razavi, Mahmood K. ; Kee, Stephen T. ; Sze, Daniel Y. ; Dake, Michael D. ; Semba, Charles P. / The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. In: Journal of vascular surgery. 2003 ; Vol. 37, No. 3. pp. 512-517.
@article{a05deb876876404d9d207e0c8ddcecc2,
title = "The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions",
abstract = "Purpose: The purpose of this study was to compare the efficacy, complications, and costs associated with low-dose (≤2 mg/h) alteplase (tissue plasminogen activator [t-PA]) versus urokinase for the catheter-directed treatment of acute peripheral arterial occlusive disease (PAO) and deep vein thrombosis (DVT). Materials and methods: A retrospective review was performed during sequential time periods on two groups with involved extremities treated with either t-PA with subtherapeutic heparin (TPA group) or urokinase with full heparin (UK group) at a single center. Treatment group characteristics, success rates, complications, dosages, infusion time, and costs were compared. Results: Eighty-nine patients with 93 involved limbs underwent treatment (54 with DVT, 39 with PAO). The treatment groups were statistically identical (TPA: 45 limbs; 24 with DVT, 53.3{\%}; 21 with PAO, 46.7{\%}; UK: 48 limbs; 30 with DVT, 62.5{\%}; 18 with PAO, 37.5{\%}). The overall average hourly infused dose, total dose, infusion time, success rates, and cost of thrombolytic agent were as follows (± standard deviation): TPA, 0.86 ± 0.50 mg/h, 21.2 ± 15.1 mg, 24.6 ± 11.2 hours, 89.4{\%}, $466 ± $331; and UK, 13.5 ± 5.6 (10 4 ) U/h, 4.485 ± 2.394 million U, 33.3 ± 13.3 hours, 85.7{\%}, $6871 ± $3667, respectively. Major and minor complication rates were: TPA, 2.2{\%} and 8.9{\%}; and UK, 2.1{\%} and 10.4{\%}, respectively. No statistical differences in success rates or complications were observed; however, t-PA was significantly (P < .05) less expensive and faster than urokinase. Conclusion: Low-dose t-PA combined with subtherapeutic heparin is equally efficacious and safe compared with urokinase. Infusions with t-PA were significantly shorter and less expensive than those with urokinase.",
author = "Koji Sugimoto and Hofmann, {Lawrence V.} and Razavi, {Mahmood K.} and Kee, {Stephen T.} and Sze, {Daniel Y.} and Dake, {Michael D.} and Semba, {Charles P.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1067/mva.2003.41",
language = "English (US)",
volume = "37",
pages = "512--517",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions

AU - Sugimoto, Koji

AU - Hofmann, Lawrence V.

AU - Razavi, Mahmood K.

AU - Kee, Stephen T.

AU - Sze, Daniel Y.

AU - Dake, Michael D.

AU - Semba, Charles P.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Purpose: The purpose of this study was to compare the efficacy, complications, and costs associated with low-dose (≤2 mg/h) alteplase (tissue plasminogen activator [t-PA]) versus urokinase for the catheter-directed treatment of acute peripheral arterial occlusive disease (PAO) and deep vein thrombosis (DVT). Materials and methods: A retrospective review was performed during sequential time periods on two groups with involved extremities treated with either t-PA with subtherapeutic heparin (TPA group) or urokinase with full heparin (UK group) at a single center. Treatment group characteristics, success rates, complications, dosages, infusion time, and costs were compared. Results: Eighty-nine patients with 93 involved limbs underwent treatment (54 with DVT, 39 with PAO). The treatment groups were statistically identical (TPA: 45 limbs; 24 with DVT, 53.3%; 21 with PAO, 46.7%; UK: 48 limbs; 30 with DVT, 62.5%; 18 with PAO, 37.5%). The overall average hourly infused dose, total dose, infusion time, success rates, and cost of thrombolytic agent were as follows (± standard deviation): TPA, 0.86 ± 0.50 mg/h, 21.2 ± 15.1 mg, 24.6 ± 11.2 hours, 89.4%, $466 ± $331; and UK, 13.5 ± 5.6 (10 4 ) U/h, 4.485 ± 2.394 million U, 33.3 ± 13.3 hours, 85.7%, $6871 ± $3667, respectively. Major and minor complication rates were: TPA, 2.2% and 8.9%; and UK, 2.1% and 10.4%, respectively. No statistical differences in success rates or complications were observed; however, t-PA was significantly (P < .05) less expensive and faster than urokinase. Conclusion: Low-dose t-PA combined with subtherapeutic heparin is equally efficacious and safe compared with urokinase. Infusions with t-PA were significantly shorter and less expensive than those with urokinase.

AB - Purpose: The purpose of this study was to compare the efficacy, complications, and costs associated with low-dose (≤2 mg/h) alteplase (tissue plasminogen activator [t-PA]) versus urokinase for the catheter-directed treatment of acute peripheral arterial occlusive disease (PAO) and deep vein thrombosis (DVT). Materials and methods: A retrospective review was performed during sequential time periods on two groups with involved extremities treated with either t-PA with subtherapeutic heparin (TPA group) or urokinase with full heparin (UK group) at a single center. Treatment group characteristics, success rates, complications, dosages, infusion time, and costs were compared. Results: Eighty-nine patients with 93 involved limbs underwent treatment (54 with DVT, 39 with PAO). The treatment groups were statistically identical (TPA: 45 limbs; 24 with DVT, 53.3%; 21 with PAO, 46.7%; UK: 48 limbs; 30 with DVT, 62.5%; 18 with PAO, 37.5%). The overall average hourly infused dose, total dose, infusion time, success rates, and cost of thrombolytic agent were as follows (± standard deviation): TPA, 0.86 ± 0.50 mg/h, 21.2 ± 15.1 mg, 24.6 ± 11.2 hours, 89.4%, $466 ± $331; and UK, 13.5 ± 5.6 (10 4 ) U/h, 4.485 ± 2.394 million U, 33.3 ± 13.3 hours, 85.7%, $6871 ± $3667, respectively. Major and minor complication rates were: TPA, 2.2% and 8.9%; and UK, 2.1% and 10.4%, respectively. No statistical differences in success rates or complications were observed; however, t-PA was significantly (P < .05) less expensive and faster than urokinase. Conclusion: Low-dose t-PA combined with subtherapeutic heparin is equally efficacious and safe compared with urokinase. Infusions with t-PA were significantly shorter and less expensive than those with urokinase.

UR - http://www.scopus.com/inward/record.url?scp=0037345953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037345953&partnerID=8YFLogxK

U2 - 10.1067/mva.2003.41

DO - 10.1067/mva.2003.41

M3 - Article

C2 - 12618684

AN - SCOPUS:0037345953

VL - 37

SP - 512

EP - 517

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 3

ER -